Avondale Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform

Go back to Avondale Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform

Leerink Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform

November 3, 2016 6:59 AM UTC

Leerink Partners downgraded Diplomat Pharmacy (NYSE: DPLO) from Outperform to Market Perform with a price target of $18.00 (from $35.00).

Analyst David Larsen commented, "Yesterday afternoon DPLO reduced its outlook for 2016 and provided a preliminary outlook for 2017 that was well below expectations. As a... More

Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance

November 2, 2016 5:16 PM UTC

Diplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of $0.21, $0.03 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $1.18 billion versus the consensus estimate of $1.26 billion.

GUIDANCE:

Diplomat Pharmacy sees FY2016 EPS of $0.83-$0.87, versus the consensus of... More